Junyuan Qi

1.4k total citations
65 papers, 848 citations indexed

About

Junyuan Qi is a scholar working on Genetics, Oncology and Hematology. According to data from OpenAlex, Junyuan Qi has authored 65 papers receiving a total of 848 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Genetics, 28 papers in Oncology and 28 papers in Hematology. Recurrent topics in Junyuan Qi's work include Chronic Lymphocytic Leukemia Research (29 papers), Lymphoma Diagnosis and Treatment (21 papers) and Multiple Myeloma Research and Treatments (17 papers). Junyuan Qi is often cited by papers focused on Chronic Lymphocytic Leukemia Research (29 papers), Lymphoma Diagnosis and Treatment (21 papers) and Multiple Myeloma Research and Treatments (17 papers). Junyuan Qi collaborates with scholars based in China, United States and France. Junyuan Qi's co-authors include Dehui Zou, Lugui Qiu, Florence Smadja‐Joffe, Gang An, Shuhua Yi, Christine Chomienne, Lugui Qiu, Michèle Allouche, C Jasmin and Zengjun Li and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Junyuan Qi

55 papers receiving 834 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Junyuan Qi China	15	488	461	294	200	177	65	848
Yuji Shimura Japan	15	227 0.5×	357 0.8×	226 0.8×	190 0.9×	100 0.6×	69	704
Nicholas Burwick United States	15	313 0.6×	393 0.9×	171 0.6×	167 0.8×	245 1.4×	36	753
Brian Parkin United States	16	374 0.8×	317 0.7×	212 0.7×	200 1.0×	198 1.1×	44	790
Mineo Kurokawa Japan	10	387 0.8×	304 0.7×	99 0.3×	131 0.7×	177 1.0×	24	728
Masaaki Takatoku Japan	18	658 1.3×	528 1.1×	323 1.1×	135 0.7×	327 1.8×	47	1.1k
BA Barut United States	11	660 1.4×	427 0.9×	457 1.6×	232 1.2×	79 0.4×	14	960
Danielle Pineau France	14	557 1.1×	354 0.8×	297 1.0×	227 1.1×	294 1.7×	19	860
Marie‐Paule Mellerin France	14	472 1.0×	415 0.9×	346 1.2×	195 1.0×	176 1.0×	18	871
Paola Storti Italy	17	515 1.1×	460 1.0×	546 1.9×	233 1.2×	57 0.3×	54	961
Afua A. Mensah Switzerland	15	309 0.6×	638 1.4×	173 0.6×	119 0.6×	143 0.8×	30	931

Countries citing papers authored by Junyuan Qi

Since Specialization

Citations

This map shows the geographic impact of Junyuan Qi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junyuan Qi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junyuan Qi more than expected).

Fields of papers citing papers by Junyuan Qi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junyuan Qi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junyuan Qi. The network helps show where Junyuan Qi may publish in the future.

Co-authorship network of co-authors of Junyuan Qi

This figure shows the co-authorship network connecting the top 25 collaborators of Junyuan Qi. A scholar is included among the top collaborators of Junyuan Qi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junyuan Qi. Junyuan Qi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sun, Mingyuan, Hongmei Jing, Fei Dong, et al.. (2024). Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma. Scientific Reports. 14(1). 27550–27550.

Qi, Junyuan, Ilseung Choi, Shuichi Ota, et al.. (2024). Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China. Clinical Pharmacology in Drug Development. 13(5). 560–571. 2 indexed citations

Qi, Junyuan, Mingyuan Sun, Keshu Zhou, et al.. (2023). EX103, a Novel CD20xCD3 Bispecific Antibody, Showed a Favorable Safety and Potent Single-Agent Antitumor Activity in Heavily Pretreated Relapsed/Refractory Patients with B-Cell Non-Hodgkin Lymphoma. Blood. 142(Supplement 1). 6230–6230. 1 indexed citations

Jiang, Bo, et al.. (2023). Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia. Frontiers in Oncology. 13. 1101738–1101738. 5 indexed citations

Sun, Mingyuan, Junyuan Qi, Lugui Qiu, et al.. (2023). A Phase 1 First-in-Human Monotherapy Study of F182112, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 142(Supplement 1). 1978–1978. 4 indexed citations

Jing, Hongmei, Yang Li, Junyuan Qi, et al.. (2022). Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003). Annals of Hematology. 101(12). 2679–2690. 3 indexed citations

Song, Yuqin, Yanyan Liu, Zhiming Li, et al.. (2022). SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial. The Lancet Haematology. 9(7). e493–e503. 32 indexed citations

Zhu, Jun, Jianyong Li, Jianfeng Zhou, et al.. (2017). BGB-3111, a Highly Specific BTK Inhibitor, Is Well Tolerated and Highly Active in Chinese Patients with Relapsed/Refractory B-Cell Malignancies: Initial Report of a Phase 1 Trial in China. Blood. 130. 5347–5347. 3 indexed citations

Deng, Shuhui, Yan Xu, Gang An, et al.. (2015). [Clinical analysis of multiple myeloma patients with bone-related extramedullary disease: a longitudinal study on 834 consecutive patients in a single center of China].. PubMed. 36(6). 501–6. 1 indexed citations

10.

Li, Zengjun, Fei Li, Shuhua Yi, et al.. (2015). Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China. BMC Cancer. 15(1). 555–555. 2 indexed citations

11.

Deng, Shuhui, Yan Xu, Gang An, et al.. (2015). Features of Extramedullary Disease of Multiple Myeloma: High Frequency of P53 Deletion and Poor Survival: A Retrospective Single-Center Study of 834 Cases. Clinical Lymphoma Myeloma & Leukemia. 15(5). 286–291. 52 indexed citations

12.

Yi, Shuhua, Rui Cui, Zengjun Li, et al.. (2014). Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenström macroglobulinemia. Chinese Medical Journal. 127(12). 2327–2331. 4 indexed citations

13.

Wang, Yini, Zhao Wang, Jia Zhang, et al.. (2014). Genetic Features of Late Onset Primary Hemophagocytic Lymphohistiocytosis in Adolescence or Adulthood. PLoS ONE. 9(9). e107386–e107386. 60 indexed citations

14.

An, Gang, Chirag Acharya, Shuhui Deng, et al.. (2014). Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment. Experimental Hematology. 43(3). 168–176.e2. 9 indexed citations

15.

Zhou, Keshu, Zhen Yu, Shuhua Yi, et al.. (2013). miR-29c down-regulation is associated with disease aggressiveness and poor survival in Chinese patients with chronic lymphocytic leukemia. Leukemia & lymphoma. 55(7). 1544–1550. 11 indexed citations

16.

Dimopoulos, Meletios Α., David S. Siegel, Sagar Lonial, et al.. (2013). Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. The Lancet Oncology. 14(11). 1129–1140. 181 indexed citations

17.

Zhang, Li, Junyuan Qi, Yafei Wang, et al.. (2010). Comparison Among Immunologically Different Subtypes of 595 Untreated Multiple Myeloma Patients in Northern China. Clinical Lymphoma Myeloma & Leukemia. 10(3). 197–204. 7 indexed citations

18.

Yi, Shuhua, Gang An, Junyuan Qi, et al.. (2010). The Significance of Bone Marrow Involvement in Aggressive Lymphomas: A Retrospective Comparison of Clinical Outcomes between Peripheral T Cell Lymphoma and Diffuse Large B Cell Lymphoma in China. Acta Haematologica. 124(4). 239–244. 6 indexed citations

19.

Xu, Yan, et al.. (2009). A Retrospective Analysis of Thirty-One Cases of Plasma Cell Leukemia from a Single Center in China. Acta Haematologica. 121(1). 47–51. 21 indexed citations

20.

Zhao, Yaozhong, Hongqiang Li, Dapeng Li, et al.. (2003). [Preliminary observation of the combination of arsenic trioxide and all-trans retinoic acid for the treatment of acute promyelocytic leukemia].. PubMed. 24(1). 32–4. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact